Trial Profile
A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 10 May 2019 Status changed from active, no longer recruiting to completed.
- 26 Feb 2019 Planned End Date changed from 15 Feb 2019 to 27 Mar 2019.
- 26 Feb 2019 Planned primary completion date changed from 15 Feb 2019 to 27 Mar 2019.